172 related articles for article (PubMed ID: 34405966)
21. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
[TBL] [Abstract][Full Text] [Related]
22. Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management.
Patel PH; Nguyen M; Rodriguez R; Surani S; Udeani G
Cureus; 2021 Jan; 13(1):e12419. PubMed ID: 33542867
[TBL] [Abstract][Full Text] [Related]
23. Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
Mack M; Frishman WH
Cardiol Rev; 2024 Jul-Aug 01; 32(4):378-383. PubMed ID: 36946979
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
[TBL] [Abstract][Full Text] [Related]
25. Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium.
Shchepkin DV; Nabiev SR; Nikitina LV; Kochurova AM; Berg VY; Bershitsky SY; Kopylova GV
Biochem Biophys Res Commun; 2020 Aug; 528(4):658-663. PubMed ID: 32513536
[TBL] [Abstract][Full Text] [Related]
26. Beneficial hemodynamic effects of milrinone in conscious rabbits with chronic aortic regurgitation.
DeFelice A; Fein S; Daudiss K; Frering R; Horan P
J Cardiovasc Pharmacol; 1989 Oct; 14(4):659-65. PubMed ID: 2478782
[TBL] [Abstract][Full Text] [Related]
27. Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.
Gladden JD; Zelickson BR; Guichard JL; Ahmed MI; Yancey DM; Ballinger S; Shanmugam M; Babu GJ; Johnson MS; Darley-Usmar V; Dell'Italia LJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(10):H1440-50. PubMed ID: 24014679
[TBL] [Abstract][Full Text] [Related]
28. The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.
Obata K; Morita H; Takaki M
Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1065-1070. PubMed ID: 31267148
[TBL] [Abstract][Full Text] [Related]
29. Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
Dashwood A; Cheesman E; Wong YW; Haqqani H; Beard N; Hay K; Spratt M; Chan W; Molenaar P
Pharmacol Res Perspect; 2021 May; 9(3):e00760. PubMed ID: 33929079
[TBL] [Abstract][Full Text] [Related]
30. Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure.
Rønning L; Bakkehaug JP; Rødland L; Kildal AB; Myrmel T; How OJ
Physiol Rep; 2018 Sep; 6(19):e13879. PubMed ID: 30311442
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
[TBL] [Abstract][Full Text] [Related]
32. Transmural compensation of myocardial deformation to preserve left ventricular ejection performance in chronic aortic regurgitation.
Iida N; Seo Y; Ishizu T; Nakajima H; Atsumi A; Yamamoto M; Machino-Ohtsuka T; Kawamura R; Enomoto M; Kawakami Y; Aonuma K
J Am Soc Echocardiogr; 2012 Jun; 25(6):620-8. PubMed ID: 22440541
[TBL] [Abstract][Full Text] [Related]
33. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy.
Ross J
J Am Coll Cardiol; 1985 Apr; 5(4):811-26. PubMed ID: 3882814
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive assessment of load reduction in patients with asymptomatic aortic regurgitation.
Wilson JR; Reichek N; Hirshfeld J
Am J Med; 1980 May; 68(5):664-74. PubMed ID: 6769329
[TBL] [Abstract][Full Text] [Related]
35. Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
Bernier TD; Buckley LF
J Cardiovasc Pharmacol; 2021 Jan; 77(1):4-10. PubMed ID: 33165138
[TBL] [Abstract][Full Text] [Related]
36. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
[TBL] [Abstract][Full Text] [Related]
37. Importance of preoperative hypertrophy, wall stress and end-systolic dimension as echocardiographic predictors of normalization of left ventricular dilatation after valve replacement in chronic aortic insufficiency.
Kumpuris AG; Quinones MA; Waggoner AD; Kanon DJ; Nelson JG; Miller RR
Am J Cardiol; 1982 Apr; 49(5):1091-100. PubMed ID: 6461239
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
[TBL] [Abstract][Full Text] [Related]
39. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Biering-Sørensen T; Böhm M; Bonderman D; Fang JC; Lanfear DE; Lund M; Momomura SI; O'Meara E; Ponikowski P; Spinar J; Flores-Arredondo JH; Claggett BL; Heitner SB; Kupfer S; Abbasi SA; Malik FI;
J Am Coll Cardiol; 2021 Jul; 78(2):97-108. PubMed ID: 34015475
[TBL] [Abstract][Full Text] [Related]
40. Echocardiographic evaluation of the response to afterload stress test in young asymptomatic patients with chronic severe aortic regurgitation: sensitivity of the left ventricular end-systolic pressure-volume relationship.
Branzi A; Lolli C; Piovaccari G; Rapezzi C; Binetti G; Specchia S; Zannoli R; Magnani B
Circulation; 1984 Oct; 70(4):561-9. PubMed ID: 6478562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
